ROBINS CHAD M 4

What Happened

• Chad M. Robins, CEO, Chairman and a director of Adaptive Biotechnologies (ADPT), sold a total of 470,167 shares in two open-market "sell" transactions on March 11, 2026.
• The sales were 140,567 shares at $13.17 each ($1,851,267) and 329,600 shares at $13.17 each ($4,340,832), totaling $6,192,099.
• These were sell-to-cover transactions to satisfy tax withholding obligations tied to the vesting of RSUs and performance share units, not discretionary cash sales.

Key Details

• Transaction date: March 11, 2026; Filing date (Form 4): March 13, 2026 (filed within the typical two-business-day window).
• Price per share: $13.17 for both tranches.
• Total shares sold: 470,167; Total proceeds: $6,192,099.
• Footnotes: F1 = sale to cover tax withholding for vested RSUs; F2 = sale to cover tax withholding for vested performance share units. These were mandated by the issuer’s equity plan ("sell to cover"), not voluntary trades by the insider.
• Shares owned after transaction: not provided in the summary data (see the full Form 4 for post-transaction holdings).

Context

• Sell-to-cover transactions are common when equity awards vest and are generally administrative (to meet tax obligations) rather than a signal of sentiment about the company. They differ from discretionary open-market sales that may reflect an insider’s view of the stock.